首頁 > 市場調查報告書 > 醫療設備

生技設備細胞培養

市場調查報告書

商品編碼

1917790

初代細胞培養市場－2026-2031年預測

Primary Cell Culture Market - Forecast from 2026 to 2031

出版日期: 2026年01月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計初代細胞培養市場將從 2025 年的 19.64 億美元成長到 2031 年的 30.89 億美元，複合年成長率為 7.84%。

由於對直接從組織中分離的細胞的需求迅速成長，初代細胞培養市場正在擴張，這推動了個人化和再生醫學的發展。研究人員正在利用生理相關的癌症模型中的初代細胞來加速藥物篩檢和治療方法檢驗。生物技術公司擴大採用酵素消化法，該方法能夠溫和、有效率地提取細胞。生物醫學研究實驗室正在拓展初代細胞3D培養的應用，以實現更逼真的體內模擬。

初代細胞培養是一種透過機械或酶解法從生物組織或器官中分離並培養細胞的技術，與永生化細胞株相比，它能保留細胞的固有特性，並具有更高的生物學相關性。這些培養系統能夠提供反映供體組織的異質性細胞群，從而可以精確模擬生理過程、藥理反應和毒理效應。在藥物研發、再生醫學和疾病建模等領域，對體內環境的逼真模擬至關重要，因此原代細胞培養市場正在穩步成長。

慢性疾病成長要素日益加重，包括癌症、糖尿病、心血管疾病、自體免疫疾病和腎臟疾病，是推動細胞治療發展的關鍵因素，因此亟需強大的臨床前治療評估平台。原代細胞在細胞和基因治療開發中的廣泛應用，凸顯了其在利用自體或異體細胞來源進行修復應用方面的重要作用。酵素消化，尤其是基於胰蛋白酶的通訊協定，因其細胞損傷小、處理速度快、產量高等優點，越來越受到青睞，優於機械處理方法。3D培養系統的進步充分利用了初代細胞固有的真實性，模擬了2D單層培養無法實現的多細胞結構和細胞外基質相互作用。動物源性初代細胞的日益普及，為疫苗生產和毒理學研究提供了支持，目前已有來自小鼠、大鼠和豬等物種的成熟模型可供使用。

從區域來看，由於醫療保健成本不斷上漲、人口老化、慢性病高發生率以及政府對生物醫學研究的大量投入，北美預計將佔據主要市場佔有率。亞太地區預計將實現強勁成長，這主要得益於幹細胞治療的成本優勢、再生醫學領域積極的研發活動以及細胞和基因療法生產能力的不斷提高。

主要企業包括 Thermo Fisher Scientific, Inc.、Lonza、Merck KGaA、Corning Incorporated 和 Danaher，它們提供全面的產品組合，包括分離試劑盒、培養基、基材和特殊試劑，這些產品針對各種細胞類型（包括上皮細胞、纖維母細胞細胞、成纖維細胞和幹細胞）的原代細胞活力、增殖和表現型產品系列。

整體而言，隨著全球對慢性病管理和個人化醫療的需求不斷成長，市場正穩步發展，並透過提高分離效率、3D 可重複性和轉化相關性，成為精準醫療、腫瘤建模和再生策略的基礎推動因素。

本報告的主要優勢：

深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略實現市場滲透的潛力。
市場促進因素與未來趨勢：探索市場促進因素和關鍵趨勢及其對未來市場發展的影響。
可操作的建議：利用這些見解，在快速變化的環境中做出策略決策，並發現新的商機和收入來源。
受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

企業如何使用我們的報告？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

研究範圍：

2021年至2025年的歷史數據和2026年至2031年的預測數據
成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
競爭定位、策略和市場佔有率分析
按業務板塊和地區分類的收入和預測評估，包括國家/地區
公司概況（策略、產品、財務資訊、關鍵發展等）

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 德國
- 法國
- 英國
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 印尼
- 泰國
- 其他

第11章競爭格局與分析

主要企業和策略分析
市佔率分析
合併、收購、協議和合作
競爭對手儀錶板

第12章：公司簡介

Thermo Fisher Scientific, Inc.
Lonza
Merck KgaA
Corning Incorporated
Danaher Corporation
PromoCell GmbH
ATCC
FUJIFILM Corporation
Mattek（Sartorius）
Axol Bioscience Ltd
STEMCELL Technologies Inc.

第13章附錄

貨幣
先決條件
基準年和預測年時間表
相關人員的主要收益
調查方法
簡稱

簡介目錄

Product Code: KSI061615763

Primary Cell Culture Market, growing at a 7.84% CAGR, is projected to achieve USD 3.089 billion in 2031 from USD 1.964 billion in 2025.

The primary cell culture market is expanding as demand surges for cells directly isolated from tissues, supporting advancements in personalized and regenerative therapies. Researchers are leveraging primary cells for physiologically relevant cancer models to accelerate drug screening and treatment validation. Biotech firms are favoring enzymatic degradation methods for gentle, high-yield cell extraction. Biomedical laboratories are broadening 3D culture applications with primary cells to achieve realistic in vivo simulations.

Primary cell culture involves isolating and cultivating cells from living tissues or organs via mechanical or enzymatic dissociation, preserving native characteristics for superior biological relevance compared to immortalized lines. These cultures offer heterogeneous populations mirroring donor tissue, enabling accurate modeling of physiological processes, pharmacological responses, and toxicological effects. The market is growing steadily, driven by needs in drug discovery, regenerative medicine, and disease modeling where fidelity to in vivo conditions is paramount.

Key growth drivers include the escalating burden of chronic diseases-such as cancer, diabetes, cardiovascular disorders, autoimmune conditions, and nephrological issues-necessitating robust preclinical platforms for therapeutic evaluation. Rising utilization in cell and gene therapy development underscores primary cells' role in manipulating autologous or allogeneic sources for restorative applications. Increasing preference for enzymatic degradation, particularly trypsin-based protocols, stems from minimized cellular damage, rapid processing, and superior yields over mechanical alternatives. Advancements in 3D culture systems capitalize on primary cells' innate realism to recapitulate multicellular architectures and extracellular matrix interactions absent in 2D monolayers. Expanding use of animal-derived primary cells supports vaccine production and toxicology studies due to well-characterized models from species like mice, rats, and pigs.

Geographically, North America is predicted to hold significant share, attributed to elevated healthcare expenditures, aging demographics, high chronic disease prevalence, and substantial government funding for biomedical research. The Asia-Pacific region is anticipated for strong growth, fueled by cost advantages in stem cell procedures, burgeoning R&D in regenerative medicine, and increasing cell/gene therapy manufacturing.

Leading companies include Thermo Fisher Scientific, Inc., Lonza, Merck KGaA, Corning Incorporated, and Danaher. These entities provide comprehensive portfolios encompassing isolation kits, culture media, substrates, and specialized reagents optimized for primary cell viability, proliferation, and phenotypic stability across epithelial, endothelial, fibroblast, and stem cell types.

Overall, the market is progressing consistently, positioned to underpin precision therapeutics, oncology modeling, and regenerative strategies through enhanced isolation efficiency, 3D fidelity, and translational relevance, as chronic disease management and personalized medicine imperatives intensify globally.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2021 to 2025 & forecast data from 2026 to 2031
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Primary Cell Culture Market Segmentation

By Cell Type
Epithelial Cell
Fibroblasts
Keratinocytes
Muscle Cells
Others
By Type
Human
Animal
By Method
Mechanical Disaggregation
Enzymatic Disaggregation
Primary Explant Technique
By Application
Cancer Research
Genetic Engineering
Vaccine Production
Virology
Drug Screening & Toxicity Testing
Others
By End-User
Pharmaceuticals & Bio-Tech Companies
Research & Academic Institute
Others
By Geography
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Indonesia
Thailand
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PRIMARY CELL CULTURE MARKET BY CELL TYPE

5.1. Introduction
5.2. Epithelial Cell
5.3. Fibroblasts
5.4. Keratinocytes
5.5. Muscle Cells
5.6. Others

6. PRIMARY CELL CULTURE MARKET BY TYPE

6.1. Introduction
6.2. Human
6.3. Animal

7. PRIMARY CELL CULTURE MARKET BY METHOD

7.1. Introduction
7.2. Mechanical Disaggregation
7.3. Enzymatic Disaggregation
7.4. Primary Explant Technique

8. PRIMARY CELL CULTURE MARKET BY APPLICATION

8.1. Introduction
8.2. Cancer Research
8.3. Genetic Engineering
8.4. Vaccine Production
8.5. Virology
8.6. Drug Screening & Toxicity Testing
8.7. Others

9. PRIMARY CELL CULTURE MARKET BY END-USER

9.1. Introduction
9.2. Pharmaceuticals & Bio-Tech Companies
9.3. Research & Academic Institute
9.4. Others

10. PRIMARY CELL CULTURE MARKET BY GEOGRAPHY

10.1. Introduction
10.2. North America
- 10.2.1. USA
- 10.2.2. Canada
- 10.2.3. Mexico
10.3. South America
- 10.3.1. Brazil
- 10.3.2. Argentina
- 10.3.3. Others
10.4. Europe
- 10.4.1. Germany
- 10.4.2. France
- 10.4.3. United Kingdom
- 10.4.4. Spain
- 10.4.5. Others
10.5. Middle East and Africa
- 10.5.1. Saudi Arabia
- 10.5.2. UAE
- 10.5.3. Israel
- 10.5.4. Others
10.6. Asia Pacific
- 10.6.1. China
- 10.6.2. India
- 10.6.3. Japan
- 10.6.4. South Korea
- 10.6.5. Indonesia
- 10.6.6. Thailand
- 10.6.7. Others